Literature DB >> 30941763

The role of BAFF and APRIL in rheumatoid arthritis.

Arezoo G Shabgah1, Zhaleh Shariati-Sarabi2, Jalil Tavakkol-Afshari1, Mojgan Mohammadi1,3.   

Abstract

Development and activation of B cells quickly became clear after identifying new ligands and receptors in the tumor necrosis factor superfamily. B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are the members of membrane proteins Type 2 family released by proteolytic cleavage of furin to form active, soluble homotrimers. Except for B cells, ligands are expressed by all such immune cells like T cells, dendritic cells, monocytes, and macrophages. BAFF and APRIL have two common receptors, namely TNFR homolog transmembrane activator and Ca2+ modulator and CAML interactor (TACI) and B cell-maturation antigen. BAFF alone can also be coupled with a third receptor called BAFFR (also called BR3 or BLyS Receptor). These receptors are often expressed by immune cells in the B-cell lineage. The binding of BAFF or APRIL to their receptors supports B cells differentiation and proliferation, immunoglobulin production and the upregulation of B cell-effector molecules expression. It is possible that the overexpression of BAFF and APRIL contributes to the pathogenesis of autoimmune diseases. In BAFF transgenic mice, there is a pseudo-autoimmune manifestation, which is associated with an increase in B-lymphocytes, hyperglobulinemia, anti-single stranded DNA, and anti-double-stranded DNA antibodies, and immune complexes in their peripheral blood. Furthermore, overexpressing BAFF augments the number of peripheral B220+ B cells with a normal proliferation rate, high levels of Bcl2, and prolonged survival and hyperactivity. Therefore, in this review article, we studied BAFF and APRIL as important mediators in B-cell and discussed their role in rheumatoid arthritis.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  APRIL; BAFF; rheumatoid arthritis

Mesh:

Substances:

Year:  2019        PMID: 30941763     DOI: 10.1002/jcp.28445

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  19 in total

1.  [Immunopathogenesis of systemic lupus erythematosus].

Authors:  Martin Aringer; Stephanie Finzel; Reinhard E Voll
Journal:  Z Rheumatol       Date:  2022-05-13       Impact factor: 1.372

2.  Increased vitreous levels of B cell activation factor (BAFF) and soluble interleukin-6 receptor in patients with macular edema due to uveitis related to Behçet's disease and sarcoidosis.

Authors:  Atsunobu Takeda; Eiichi Hasegawa; Nobuyo Yawata; Shoji Notomi; Keijiro Ishikawa; Yusuke Murakami; Toshio Hisatomi; Kazuhiro Kimura; Koh-Hei Sonoda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-01       Impact factor: 3.535

3.  Synergistic effect of Bruton's tyrosine kinase and TNF-α in the regulation of rheumatoid arthritis and underlying mechanisms.

Authors:  Jinwan Du
Journal:  Exp Ther Med       Date:  2021-12-14       Impact factor: 2.447

Review 4.  B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.

Authors:  Hanley N Abramson
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

5.  Periodontal Health and Oral Microbiota in Patients with Rheumatoid Arthritis.

Authors:  Kaja Eriksson; Guozhong Fei; Anna Lundmark; Daniel Benchimol; Linkiat Lee; Yue O O Hu; Anna Kats; Saedis Saevarsdottir; Anca Irinel Catrina; Björn Klinge; Anders F Andersson; Lars Klareskog; Karin Lundberg; Leif Jansson; Tülay Yucel-Lindberg
Journal:  J Clin Med       Date:  2019-05-08       Impact factor: 4.241

6.  Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019.

Authors:  Huijuan Zhang; Haoze Zhang; Dai Gao; Wenhui Xie; Yan Geng; Zhuoli Zhang
Journal:  Arthritis Res Ther       Date:  2020-05-01       Impact factor: 5.156

Review 7.  Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage.

Authors:  Julien Blaess; Julia Walther; Arthur Petitdemange; Jacques-Eric Gottenberg; Jean Sibilia; Laurent Arnaud; Renaud Felten
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-16       Impact factor: 5.346

Review 8.  Innate immunity drives pathogenesis of rheumatoid arthritis.

Authors:  Maria I Edilova; Ali Akram; Ali A Abdul-Sater
Journal:  Biomed J       Date:  2020-07-08       Impact factor: 4.910

9.  Possible Anti-inflammatory Effects of Mesenchymal Stem Cells Transplantation via Changes in CXCL8 Levels in Patients with Refractory Rheumatoid Arthritis.

Authors:  Arezoo Gowhari Shabgah; Zhaleh Shariati-Sarabi; Jalil Tavakkol-Afshari; Mohsen Ghoryani; Mojgan Mohammadi
Journal:  Int J Mol Cell Med       Date:  2019

10.  Serum a proliferation-inducing ligand and MicroRNA-223 are associated with rheumatoid arthritis: diagnostic and prognostic implications.

Authors:  Mohamed Taha; Olfat Gamil Shaker; Enas Abdelsalam; Noha Taha
Journal:  Mol Med       Date:  2020-10-01       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.